Thursday, Tibotec Pharmaceuticals announced results from two pivotal Phase 3, double-blind, randomized clinical trials comparing the efficacy, safety and tolerability of its investigational non-nucleoside reverse transcriptase inhibitor TMC278 or rilpivirine versus efavirenz, each administered once daily with a nucleoside/nucleotide background regimen in treatment-naive, HIV-1-infected adults.
The company said the global trials, known as ECHO and THRIVE, reached their primary objective, which was to demonstrate non-inferiority of TMC278 vs.
Tibotec has also entered into a license and collaboration agreement with Gilead Sciences, Inc. (GILD) for the development and commercialization of a once-daily, fixed-dose combination of TMC278 and Gilead's Truvada.
For comments and feedback: editorial@rttnews.com